These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20232116)

  • 21. Basis for dosing time-dependent changes in the antiviral activity of interferon-alpha in mice.
    Ohdo S; Wang DS; Koyanagi S; Takane H; Inoue K; Aramaki H; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2000 Aug; 294(2):488-93. PubMed ID: 10900223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
    Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
    Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis.
    Lepist EI; Jusko WJ
    J Vet Pharmacol Ther; 2004 Aug; 27(4):211-8. PubMed ID: 15305849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and interspecies scaling of recombinant human factor VIII.
    Mordenti J; Osaka G; Garcia K; Thomsen K; Licko V; Meng G
    Toxicol Appl Pharmacol; 1996 Jan; 136(1):75-8. PubMed ID: 8560482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Localization of a receptor nonapeptide with a possible role in the binding of the type I interferons.
    Eid P; Langer JA; Bailly G; Lejealle R; Guymarho J; Tovey MG
    Eur Cytokine Netw; 2000 Dec; 11(4):560-73. PubMed ID: 11125298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine (AZT) in several mammalian species.
    Patel BA; Boudinot FD; Schinazi RF; Gallo JM; Chu CK
    J Pharmacobiodyn; 1990 Mar; 13(3):206-11. PubMed ID: 2115580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2.
    Bazin-Redureau M; Pepin S; Hong G; Debray M; Scherrmann JM
    Toxicol Appl Pharmacol; 1998 Jun; 150(2):295-300. PubMed ID: 9653060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
    Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C
    J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP).
    Choi S; Han S; Jeon S; Yim DS
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31311144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity.
    Khine AA; Lingwood CA
    J Cell Physiol; 2000 Jan; 182(1):97-108. PubMed ID: 10567921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans.
    Mager DE; Jusko WJ
    Pharm Res; 2002 Oct; 19(10):1537-43. PubMed ID: 12425473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of NS-49, a phenethylamine class alpha(1A)-adrenoceptor agonist, at therapeutic doses in several animal species and interspecies scaling of its pharmacokinetic parameters.
    Mukai H; Watanabe S; Tsuchida K; Morino A
    Int J Pharm; 1999 Sep; 186(2):215-22. PubMed ID: 10486440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the in vitro host range of recombinant met-interferon-con1, interferon-alpha 2b, and interferon-beta [corrected].
    Hu CJ; Ozes ON; Klein SB; Blatt LM; Taylor MW
    J Interferon Cytokine Res; 1995 Mar; 15(3):231-4. PubMed ID: 7584668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells.
    Buckwold VE; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):62-70. PubMed ID: 16867173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
    García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I;
    BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
    Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
    Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine.
    Yassen A; Olofsen E; Kan J; Dahan A; Danhof M
    Clin Pharmacokinet; 2007; 46(5):433-47. PubMed ID: 17465641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of type I interferons on Friend retrovirus infection.
    Gerlach N; Schimmer S; Weiss S; Kalinke U; Dittmer U
    J Virol; 2006 Apr; 80(7):3438-44. PubMed ID: 16537611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The comparative anti-herpes simplex virus effects of human interferons.
    Taylor JL; Little SD; O'Brien WJ
    J Interferon Cytokine Res; 1998 Mar; 18(3):159-65. PubMed ID: 9555977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.